A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
| Excerpt | Reference |
|---|
| "Familial hypercholesterolemia is a prototype for a class of diseases that result from defects in receptor molecules." | ( Brown, MS; Goldstein, JL, 1978) |
| "Thus, familial hypercholesterolemia is as highly atherogenic as that of the Western countries even in Japan where the low incidence of coronary heart disease in the general population has been attributed to the low level of serum cholesterol." | ( Haba, T; Ito, S; Kametani, T; Koizumi, J; Mabuchi, H; Miyamoto, S; Ohta, M; Takeda, R; Takegoshi, T; Takeshita, H; Tatami, R; Ueda, K; Ueda, R, 1977) |
| "Hypercholesterolemia is one of the major risk factors for ischemic heart disease and for the development of atherosclerotic plaques." | ( Bürgisser, E; Dubach, UC; Erne, P; Longauer, M; Schmidt, E, 1992) |
| "This indicates that hypercholesterolemia is accompanied in hypertensive patients by marked changes in platelet fatty acid composition, cyclic AMP content and response to aggregating agents." | ( Devynck, MA; Driss, F; Duranthon, V; Le Quan Sang, KH; Levenson, J; Mazeaud, MM; Simon, A, 1992) |
| "This marked hypercholesterolemia is primarily due to elevated levels of very low and intermediate density lipoproteins." | ( Aalto-Setälä, K; Breslow, JL; Hayek, T; Plump, AS; Rubin, EM; Smith, JD; Verstuyft, JG; Walsh, A, 1992) |
| "Hypercholesterolemia is common in preterm infants administered 10% Intralipid perhaps because of excess phospholipid in plasma causing efflux of cholesterol from tissues." | ( Hamilton, JJ; Innis, SM; Phang, M, 1992) |
| "Hypercholesterolemia is commonly associated with primary biliary cirrhosis." | ( Crippin, JS; Dickson, ER; Harrison, JM; Jorgensen, R; Kottke, BA; Lindor, KD; Murtaugh, PA, 1992) |
| "In this model, hypercholesterolemia is a pathogenetic factor in glomerular injury only when it coexists with systemic hypertension." | ( Raij, L; Stone, BG; Tolins, JP, 1992) |
| "Although hypercholesterolemia is a frequent complication in cardiac transplant recipients, the exact mechanisms contributing to its development are not known." | ( Bolman, RM; Hertz, MI; Hunninghake, DB; Knutson, KR; Kubo, SH; Olivari, MT; Peters, JR, 1992) |
| "Hypercholesterolemia is a significant risk factor for coronary heart disease, and the hypocholesterolemic effects of psyllium are well established." | ( Anderson, JW; Balm, TK; Floore, TL; Geil, PB; O'Neal, DS, 1991) |
| "Hypercholesterolemia is a problem not only shared by many adults but also by their children." | ( Hannaman, KN; Schifman, V, 1989) |
| "This hypercholesterolemia is due to an increased cholesterol content in VLDL and chylomicrons." | ( Cardona-Sanclemente, LE; Ferezou, J; Lutton, C, 1988) |
| "Hypercholesterolemia is the result of an imbalance between two basic cholesterol homeostatic mechanisms." | ( Joossens, JV, 1988) |
| "Although hypercholesterolemia is not the only cause of atherosclerosis, a large body of evidence has identified it as a determining cause in many cases." | ( Steinberg, D, 1987) |
| "The hypercholesterolemia is due in part to a fourfold increase in activity of hepatic HMG-CoA reductase, the rate-limiting step in cholesterol biosyntheses." | ( Naseem, SM; Rogers, EL, 1981) |
| "Hypercholesterolemia is best managed with diet and, if necessary, colestipol and niacin." | ( Saudek, CD, 1982) |
| "In many diabetics, hypercholesterolemia is present and further exacerbates this risk." | ( Cressman, MD; Ganda, OP; Lodewick, PA; McGovern, ME; Phillipson, B; Raskin, P; Rosenstock, J; Schwartz, S; Weiner, B; Willard, D, 1995) |
| "Hypercholesterolemia is a risk factor for coronary disease, and platelet reactivity is increased with hypercholesterolemia, suggesting a prethrombotic risk." | ( Hung, J; Lacoste, L; Lam, JY; Letchacovski, G; Solymoss, CB; Waters, D, 1995) |
| "Thus, hypercholesterolemia is associated with an enhanced platelet thrombus formation on an injured artery, increasing the propensity for acute thrombosis." | ( Hung, J; Lacoste, L; Lam, JY; Letchacovski, G; Solymoss, CB; Waters, D, 1995) |
| "Hypercholesterolemia is common following renal transplantation and undoubtedly contributes to morbidity and mortality due to occlusive atherosclerosis in these patients." | ( Goldberg, RB; Roth, D, 1995) |
| "Hypercholesterolemia is common after cardiac transplantation and may contribute to the development of coronary vasculopathy." | ( Chia, D; Cogert, GA; Johnson, JA; Katznelson, S; Kobashigawa, JA; Laks, H; Sabad, A; Terasaki, PI; Wang, XM; Yeatman, L, 1995) |
| "Hypercholesterolemia is a major risk factor for coronary artery disease (CAD)." | ( Carey, M; Johnson, EQ; Lynch, MM; McGehee, MM; Rasmussen, HM; Sahyoun, N, 1995) |
| "Hypercholesterolemia is a predisposing factor for atherosclerosis." | ( Di Nardo, P; Di Sciullo, A; Kolpakov, V; Mironov, A; Nasuti, M; Poggi, A, 1994) |
| "Hypercholesterolemia is an important contributor to the development of intimal hyperplasia and superimposed accelerated atherosclerosis in vein bypass grafts." | ( Barber, L; Dalen, H; Davies, MG; Hagen, PO; Kim, JH; Klyachkin, ML; Svendsen, E, 1994) |
| "Sustained hypercholesterolemia is a known risk factor for development of atherosclerosis." | ( Burgin, CW; Cerda, JJ; Leelachaikul, P; Normann, SJ; Robbins, FL; Sullivan, MP; Vathada, S, 1994) |
| "Hypercholesterolemia is characterized by a coronary vasoconstrictive response to the endothelium-dependent vasodilator acetylcholine." | ( Burnett, JC; Chesebro, JH; Edwards, WD; Fuster, V; Lerman, A; Webster, MW; Wei, CM, 1993) |
| "Hypercholesterolemia is associated with an increased incidence of vascular complications." | ( Kageyama, S; Kaneko, T; Minamikawa, K; Mori, Y; Nakase, T; Ohiwa, M; Tamaki, S; Tanigawa, M; Wada, H; Wakita, Y, 1993) |
| "Hypertension and hypercholesterolemia are frequently associated with this leading to considerable cardiovascular risk." | ( Alcázar de la Osa, JM; Fernández Pinilla, C; Luque Otero, M; Martell Claros, N; Rodicio Díaz, JL; Ruilope Urioste, LM, 1993) |
| "Hypercholesterolemia is an important risk factor for the development of atherosclerosis." | ( Barber, L; Davies, MG; Hagen, PO; Kim, JH; Klyachkin, ML; Massey, MF; McCann, RL; Svendsen, E, 1993) |
| "Hypercholesterolemia is well known as a risk factor which had been shown to affect the long-term prognosis after coronary artery bypass grafting (CABG)." | ( Agishi, T; Dohi, T; Endo, M; Fujiwara, T; Ito, T; Kawashima, Y; Kitamura, S; Kito, Y; Matsuda, H; Takahashi, J, 1993) |
| "One form of hypercholesterolemia is characterized by high levels of LDL cholesterol and normal levels of LDL-apolipoprotein (apo) B." | ( Grundy, SM; Vega, GL, 1996) |
| "Hypercholesterolemia is a well-known CHD risk factor." | ( Geurian, KL, 1996) |
| "Hypercholesterolemia is a major risk factor for coronary atherosclerosis and most developed countries currently have public health strategies that attempt to reduce the level of cholesterol." | ( Cardoso-Saldaña, G; Lerman-Garber, I; Posadas-Romero, C; Salvatierra-Izaba, B; Sepúlveda-Amor, JA; Tapia-Conyer, R; Zamora-González, J, 1995) |
| "This response to hypercholesterolemia is interesting because the activity of the smooth muscle cells differs from that observed in the classic lesion: they intervene earlier, their replication is very marked and rapid, their elastin secretion is greater and remains constant over time, and their phagocytic properties are reduced." | ( Aouidet, A; Bouissou, H; De Graeve, J; Julian, M; Kokolo, J; Pieraggi, MT; Thiers, JC, 1996) |
| "Hypercholesterolemia is associated with increased platelet reactivity and changes in megakaryopoiesis, which might influence the synthesis of growth factors in the megakaryocyte." | ( Alegría, E; García Bolao, I; Gil, MJ; Grau, A; Martínez, A; Martínez-Caro, D; Merino, J, 1996) |
| "Hypercholesterolemia is associated with platelet activation." | ( Angelin, B; Bröijersén, A; Eriksson, M; Hjemdahl, P; Leijd, B, 1997) |
| "Therapy of hypercholesterolemia is recommended to at least mitigate the fatty intimal proliferation of GV." | ( Esper, E; Filer, SR; Glagov, S; Karp, RB; Sand, ME; Scanu, AM; Simonsen, KK, 1997) |
| "Experimental hypercholesterolemia is associated with coronary vasomotor dysfunction." | ( Barber, DA; Cannan, CR; Hasdai, D; Holmes, DR; Lerman, A; Mathew, V; Miller, VM; Schwartz, RS, 1997) |
| "Experimental hypercholesterolemia is associated with coronary endothelial dysfunction and increased circulating endothelin concentrations." | ( Hasdai, D; Holmes, DR; Katusic, ZS; Lerman, A; Mathew, V; Schwartz, RS; Smith, LA, 1997) |
| "Hypercholesterolemia is a consistent feature of the nephrotic syndrome." | ( al-Shurbaji, A; Berglund, L; Humble, E; Lindenthal, B; Rudling, M, 1998) |
| "Hypercholesterolemia is known to affect the responsiveness of various blood vessels to endogenous and to exogenous vasoactive agents." | ( el-Sherbeeny, M; Khayyal, MA; Khayyal, MT; Okpanyi, SN; Schneider, W; Sharaf, HM, 1998) |
| "Hypercholesterolemia is prevalent in the Northern part of Mexico and might be associated to dietary habits and sedentary lifestyle." | ( Fernandez, ML; Galaviz, S; Romero, AL; Romero, JE, 1998) |
| "Serum hypercholesterolemia is theorized to accelerate atherogenesis by augmenting cholesterol accumulation (insudation) in the arterial intima." | ( Sloop, GD, 1999) |
| "Hypercholesterolemia is a central pathogenic factor of endothelial dysfunction caused in part by an impairment of endothelial nitric oxide (NO) production through mechanisms that remain poorly characterized." | ( Balligand, JL; Desager, JP; Dessy, C; Feron, O; Moniotte, S, 1999) |
| "Hypercholesterolemia is associated with AT1-receptor upregulation, endothelial dysfunction, and increased NADH-dependent vascular O2*- production." | ( Böhm, M; Bräsen, JH; Griendling, KK; Harrison, DG; Heitzer, T; Macharzina, R; Meinertz, T; Münzel, T; Nickenig, G; Schulz, E; Skatchkov, M; Stasch, JP; Warnholtz, A, 1999) |
| "Experimental hypercholesterolemia is associated with coronary atherogenesis and altered vasomotor regulation." | ( Cohen, P; Hasdai, D; Holmes, DR; Lerman, A; Nielsen, MF; Richardson, DM; Rizza, RA, 1999) |
| "Hypercholesterolemia is a well-known complication in kidney transplant recipients, although its pathogenesis may be multifactorial." | ( Endo, T; Horii, A; Kamata, K; Kobayashi, N; Nakamura, M; Okubo, M; Sato, K; Takeuchi, Y; Tsukamoto, Y, 1999) |
| "Post-transplant hypercholesterolemia is featured with abnormalities in very low-density lipoprotein (VLDL) metabolism." | ( Endo, T; Horii, A; Kamata, K; Kobayashi, N; Nakamura, M; Okubo, M; Sato, K; Takeuchi, Y; Tsukamoto, Y, 1999) |
| "Hypercholesterolemia is associated with increased circulating and tissue endothelin-1 immunoreactivity, decreased nitric oxide (NO) activity, and altered endothelial function." | ( Best, PJ; Holmes, DR; Lerman, A; Lerman, LO; Richardson, D; Romero, JC, 1999) |
| "Hypercholesterolemia is a primary risk factor for atherosclerosis, coronary artery disease, and myocardial infarction." | ( Aw, TY; Girod, WG; Jones, SP; Lefer, DJ; Sieber, N, 1999) |
| "Hypercholesterolemia is a major risk factor for coronary atherosclerosis." | ( Lai, MM; Li, TC; Lin, CC; Liu, CS, 1999) |
| "Familial hypercholesterolemia is defined by a genetically elevated concentration of plasma cholesterol." | ( Alonso-Villaverde, C; Heras, M; Masana, L; Pedro-Botet, JC; Pérez-Jiménez, F; Ros-Rahola, E; Sardà, P; Vallbé, JC, 1999) |
| "Hypercholesterolemia is a major cardiovascular risk factor." | ( Charoenkiatkul, S; Chitchumroonchokchai, C; Kosulwat, V; Mahachoklertwattana, P; Rojroongwasinkul, N; Suthutvoravut, U, 1999) |
| "Hypercholesterolemia is a major risk factor initiating and accelerating atherosclerosis and leading to severe stages of coronary artery disease (CAD) with a high risk of cardiovascular events." | ( Abletshauser, CB; Eichstädt, HW; Störk, T; Weidinger, G, 2000) |
| "Hypercholesterolemia is a major risk factor for coronary heart disease and nutrition management is the initial therapeutic approach." | ( Allgood, LD; Anderson, JW; Blonde, L; Brown, WV; Davidson, MH; Ginsberg, H; Howard, WJ; Weingand, KW, 2000) |
| "Hypercholesterolemia is an independent risk factor for kidney graft loss from chronic rejection in male patients with previous acute rejection." | ( Abramowicz, D; Broeders, N; Vereerstraeten, P; Wissing, KM, 2000) |
| "In vivo, hypercholesterolemia is associated with an altered balance between NO-mediated and NO-independent K(Ca) channel contributions to resting vasomotor tone and impairment of both mechanisms of endothelium-dependent vasodilatation." | ( Jeremy, RW; McCarron, H, 2000) |
| "Because hypercholesterolemia is a major risk factor for coronary artery disease and oxidative modification of low-density lipoprotein (LDL) may be involved in atherogenesis, we investigated whether daily supplements of placebo, or alpha-, gamma-, or delta- (alpha-, gamma-, or delta-) tocotrienyl acetates would alter serum cholesterol or LDL oxidative resistance in hypercholesterolemics in a double-blind placebo controlled study." | ( Baldenius, K; Devaraj, S; Grundy, S; Hoppe, PP; Jialal, I; Kraemer, K; O'Byrne, D; Packer, L; Traber, MG, 2000) |
| "Experimental hypercholesterolemia is associated with an increase in coronary vasoconstrictor response to endothelin-1 in vivo, although the relative contributions of subtypes of endothelin receptor in this model remain unknown." | ( Barber, DA; Hasdai, D; Holmes, DR; Lerman, A; Mathew, V; Miller, VM, 2000) |
| "Hypercholesterolemia is a recognized risk factor for development of atherosclerosis in both native coronary arteries and bypass grafts." | ( Christenson, JT, 2001) |
| "Hypercholesterolemia is associated with endothelial dysfunction and atherosclerotic lesion formation." | ( Badimon, L; Martínez-González, J; Rodríguez, C; Sánchez-Gómez, S, 2001) |
| "We conclude that hypercholesterolemia is associated with calcific aortic stenosis and may be implicated in its pathogenesis and progression." | ( Bloomfield, P; Boon, NA; Chui, MC; Newby, DE; Panarelli, M, 2001) |
| "Hypercholesterolemia is a major risk factor for the development of coronary heart disease." | ( Arai, Y; Funatsu, T; Kakuta, H; Miyata, K; Suzuki, K; Tanaka, H, 2001) |
| "Hypercholesterolemia is a common clinical metabolic and/or genetic disorder that promotes functional and structural vascular wall injury." | ( Lerman, LO; Napoli, C, 2001) |
| "Experimental hypercholesterolemia is associated with vasa vasorum neovascularization, unknown to occur before or after initial lesion formation." | ( Herrmann, J; Holmes, DR; Lerman, A; Lerman, LO; Richardson, DM; Ritman, EL; Rodriguez-Porcel, M, 2001) |
| "Hypercholesterolemia is a prominent risk factor for coronary artery disease (CAD), yet cholesterol metabolism has not been evaluated in women with CAD." | ( Gylling, H; Miettinen, TA; Rajaratnam, RA, 2001) |
| "Hypercholesterolemia is characterized by elevated plasma levels of LDL in which the cholesteryl ester (CE)-rich LDL subclasses of light and intermediate density (LDL1+2 and LDL3, respectively) typically predominate." | ( Bruckert, E; Chancharme, L; Chapman, MJ; Mallet, A; Nigon, F; Thérond, P; Zarev, S, 2002) |
| "Hypercholesterolemia is a risk factor for atherosclerosis-causing endothelial dysfunction, an early event in the disease process." | ( Binggeli, C; Corti, R; Hürlimann, D; Lang, MG; Lerch, PG; Lüscher, TF; Noll, G; Ruschitzka, F; Spieker, LE; Sudano, I, 2002) |
| "In addition, hypercholesterolemia is associated with the loss of nitric oxide-induced vasodilation and the subsequent increase in blood pressure." | ( Dressman, J; Febbraio, M; Guerin, TM; Guo, L; Kincer, JF; Smart, EJ; Uittenbogaard, A, 2002) |
| "Experimental hypercholesterolemia is associated with increased expression of ET-1, an endothelium-derived peptide with vasoconstricting, mitogenic and angiogenic properties, in the coronary arterial wall as well as with vasa vasorum neovascularization." | ( Best, PJ; Herrmann, J; Holmes, DR; Lerman, A; Lerman, LO; Ritman, EL, 2002) |
| "Hypercholesterolemia is associated with high plasma levels of ISP." | ( Engström, G; Hedblad, B; Janzon, L; Lind, P; Lindgärde, F; Stavenow, L, 2002) |
| "Hypercholesterolemia is associated with inflammation and the prothrombotic state." | ( Cipollone, F; Cuccurullo, F; Davì, G; Di Febbo, C; Falco, A; Fazia, M; Mezzetti, A; Nutini, M; Porreca, E, 2002) |
| "The treatment of hypercholesterolemia is regularly limited by non compliance over the long-term." | ( Bruckert, E; Clavel, T; Consoli, SM; Marcantoni, JP, 2002) |
| "Both menopause and hypercholesterolemia are associated with endothelial dysfunction and increased coronary risk." | ( Chayama, K; Higashi, Y; Kimura, M; Kodama, I; Nakagawa, K; Ohama, K; Sanada, M; Tsuda, M, 2002) |
| "Hypercholesterolemia is associated with endothelial dysfunction." | ( d'Uscio, LV; Katusic, ZS; Kovesdi, I; O'Brien, T; Zanetti, M, 2003) |
| "Hypercholesterolemia is an important risk factor for cardiovascular disease." | ( Bokura, H; Kobayashi, S, 2003) |
| "Hypercholesterolemia is linked to endothelial dysfunction and enhancement of the endogenous inhibitor of NO synthase." | ( Abdalla, DS; Bersch, D; Bertolami, MC; Faludi, AA; Pereira, EC; Salem, M, 2003) |
| "Experimental hypercholesterolemia is characterized by increased endothelin-1 (ET-1) activity and is associated with an attenuated myocardial perfusion response and an inappropriate increase in coronary microvascular permeability during episodes of increased myocardial demand." | ( Best, PJ; Bonetti, PO; Holmes, DR; Lerman, A; Lerman, LO; Rodriguez-Porcel, M, 2003) |
| "Postmenopausia and hypercholesterolemia are related to endothelial dysfunction, a pathogenic event in atherosclerosis." | ( Castillo, OA; Cuevas, AM; Germain, AM; Irribarra, VL; Yañez, MD, 2003) |
| "As hypercholesterolemia is a major cause of endothelial dysfunction, it may interfere with these responses." | ( Barreto-Filho, JA; Chacra, AP; Consolim-Colombo, FM; Guerra-Riccio, GM; Krieger, EM; Krieger, JE; Lopes, HF; Martinez, T; Santos, RD; Teixeira, SH, 2003) |
| "Hypercholesterolemia is a risk factor for coronary heart disease (CHD) and also could contribute to impaired immune response." | ( Ausman, LM; Han, SN; Leka, LS; Lichtenstein, AH; Meydani, SN, 2003) |
| "Hypercholesterolemia is combined with enhanced lipid peroxidation, which can promote atherogenesis by inducing endothelial adhesion molecule expression." | ( Broccoletti, S; Croce, G; Desideri, G; Ferri, C; Passacquale, G; Santucci, A; Tucci, M; Valeri, L, 2003) |
| "Although hypercholesterolemia is a well-established risk factor for coronary artery disease, little is known regarding its direct effects on cardiac function." | ( Hanley, F; Houser, SR; Huang, Y; Narula, J; Tulenko, TN; Walker, KE, 2004) |
| "Hypercholesterolemia is a major health risk." | ( Berger, A; Fay, LB; Piguet-Welsch, C; Pouteau, E, 2003) |
| "Hypercholesterolemia is a major risk factor for coronary artery disease." | ( Devaraj, S; Jialal, I; Vega-López, S, 2004) |
| "Hypercholesterolemia is prevalent in pediatric cardiac transplant recipients." | ( Backer, C; Crawford, SE; Mavroudis, C; Pahl, E; Rodgers, S; Seipelt, IM; Seipelt, RG, 2004) |
| "Hypercholesterolemia is frequent after heart transplantation." | ( Banner, NR; Barbir, M; Mitchell, AG; O'Rourke, B; Yacoub, MH, 2004) |
| "Hypercholesterolemia is associated with impaired endothelial function, and human studies using cholesterol-lowering drugs indicate that endothelial function in the coronary arteries improves with reduction of serum LDL cholesterol over 6 to 12 months." | ( Horimoto, M; Igarashi, K; Nishimura, M; Tsuji, M, 2004) |
| "Hypercholesterolemia is the dominant risk factor associated with atherothrombotic disorders in the western world." | ( Basili, S; Davì, G; Falco, A; Ferroni, P, 2004) |
| "Hypertension and hypercholesterolemia are frequently associated, and their treatment is proven to reduce cardiovascular risk." | ( Cesari, M; Pessina, AC, 2004) |
| "Hypercholesterolemia is caused by multiple environmental factors and genetic predispositions, and plays an important role in the development and pathogenesis of various human diseases." | ( Aigner, B; de Angelis, MH; Klempt, M; Mohr, M; Rathkolb, B; Wolf, E, 2004) |
| "Hypercholesterolemia is a common disorder after heart transplantation and my be associated with the development of transplant coronary artery disease." | ( Bilińska, M; Wolszakiewicz, J, 2004) |
| "Severe hypercholesterolemia is an important, and likely more common than previously reported, long-term complication of allogeneic hematopoietic stem cell transplantation." | ( Graham, T; Longo, W; Seely, EW; Soiffer, R; Turchin, A; Wiebe, DA, 2005) |
| "Hypercholesterolemia is an important risk factor for coronary heart disease." | ( Bozbas, H; Guz, G; Korkmaz, ME; Muderrisoglu, H; Ozin, MB; Tayfun, E; Yigit, F, 2004) |
| "Although hypercholesterolemia is a strong risk factor for cardiovascular disease, it has in some instances paradoxically been associated with reduced infarct size and preserved contractile function in isolated hearts after ischemia and reperfusion." | ( Breukelmann, D; d'Uscio, LV; Dworschak, M; Hannon, JD, 2005) |
| "The presence of hypercholesterolemia is currently not considered a selection criteria for performing gastric restrictive or diversionary bariatric surgery." | ( Attili, AF; Badiali, M; Batta, AK; Cornoldi, A; Corradini, SG; Eramo, A; Grossi, A; Liguori, F; Lubrano, C; Pisanelli, MC; Salen, G; Siciliano, M; Spera, G, 2005) |
| "Hypercholesterolemia is associated with increased cardiovascular mortality and is known to promote the advancement of atherosclerotic lesions in experimental animal models." | ( Friedman, MH; Himburg, HA; Lamack, JA, 2006) |
| "Hypercholesterolemia is found in patients with hypothyroidism and resistance to thyroid hormone." | ( Cohen, RN; Hashimoto, K; Markan, KR; Monden, T; Mori, M; Satoh, T; Wondisford, FE; Yamada, M, 2006) |
| "Hypercholesterolemia is a major risk factor for erectile dysfunction (ED), but the mechanisms are not completely understood." | ( Annex, BH; Donatucci, CF; Kontos, CD; Xie, D, 2005) |
| "Hypercholesterolemia is a dominant risk factor for the development and progression of atherosclerosis and cardiovascular diseases." | ( Chan, AS; Chan, SW; Chen, SL; Ma, XJ; Xu, HX; Yan, LP, 2006) |
| "Hypercholesterolemia is considered a major risk factor in the development of atherosclerotic disease." | ( Pfister, SL, 2006) |
| "Thus, the hypercholesterolemia is primarily caused by increased hepatic production of cholesterol-rich VLDL, as demonstrated by the increases in plasma cholesterol levels after intravenous injection of Triton WR1339." | ( Arai, H; Iizuka, Y; Inaba, T; Ishibashi, S; Isoo, N; Kadowaki, T; Kitamine, T; Nagai, RZ; Ohashi, K; Okazaki, H; Okazaki, M; Okazaki, S; Osuga, J; Sekiya, M; Shibata, N; Shimano, H; Tazoe, F; Tozawa, R; Tsukamoto, K; Yagyu, H; Yahagi, N, 2006) |
| "Hypercholesterolemia is a potential risk factor for asthma independent of obesity." | ( Abu-Hasan, M; Al-Huniti, N; Al-Shawwa, B; Titus, G, 2006) |
| "Hypercholesterolemia is a major risk factor involved in abnormal cardiovascular events." | ( Esato, K; Guo, F; Hamano, K; Kishi, H; Kobayashi, S; Morikage, N; Sato, M; Shirao, S; Soma, M; Yano, T, 2006) |
| "Hypercholesterolemia is an important paraneoplastic syndrome in patients with hepatoma, but the nature of this defect has not yet been identified." | ( Doy, M; Hirayama, T; Honda, A; Ikegami, T; Lea, M; Matsuzaki, Y; Miyazaki, T; Salen, G; Xu, G, 2006) |
| "Hypercholesterolemia is a frequent complication in renal transplant patients treated with cyclosporine A (CsA)." | ( Abramowicz, D; Berkenboom, G; Broeders, N; Carpentier, Y; Ghisdal, L; Unger, P; Wissing, KM, 2006) |
| "Hypercholesterolemia is a potential trigger of Alzheimer's disease, and is thought to increase brain levels of beta-amyloid (Abeta) and iron." | ( Ghribi, O; Golovko, MY; Larsen, B; Murphy, EJ; Schrag, M, 2006) |
| "Hypercholesterolemia is a major risk factor for atherosclerosis." | ( Bitzur, R; Cohen, H; Harats, D, 2006) |
| "In summary, hypercholesterolemia is associated with enhancement of inflammatory response, oxidative stress, and ATP and ADP hydrolysis." | ( Bem, AF; Dorneles, A; Duarte, MM; Leal, DB; Loro, VL; Morsch, VM; Rocha, JB; Schetinger, MR, 2007) |
| "Hypercholesterolemia is associated with oxidative stress and endothelial dysfunction in cerebral arterioles, despite the absence of atherosclerotic lesions." | ( Faraci, FM; Heistad, DD; Kitayama, J; Lentz, SR, 2007) |
| "Hypercholesterolemia is characterized with changes in lipid profile, nitric oxide pathway and oxidative stress markers." | ( Altug, T; Aslan, M; Balci, H; Bolayirli, IM; Hacibekiroglu, M; Seven, A, 2007) |
| "Hypercholesterolemia is one of the most important risk factors for the development of erectile dysfunction (ED) in men." | ( Annex, BH; Donatucci, CF; Odronic, SI; Pippen, AM; Wu, F; Xie, D, 2007) |
| "Hypercholesterolemia is a well-established risk factor for mortality and morbidity in coronary heart disease." | ( Araújo, JP; Azevedo, A; Bettencourt, P; Ferreira, A; Friões, F; Lourenço, P; Rocha-Gonçalves, F, 2008) |
| "Maternal hypercholesterolemia is associated with a higher incidence and faster progression of atherosclerotic lesions in neonatal offspring." | ( Alkemade, FE; DeRuiter, MC; Gittenberger-de Groot, AC; Havekes, LM; Hogers, B; Poelmann, RE; Schiel, AE; van Vliet, LS; VanMunsteren, JC; Willems van Dijk, K, 2007) |
| "Hypercholesterolemia is an important risk factor for cardiovascular disease (CVD)." | ( Jaffer, S; Sampalis, JS, 2007) |
| "Hypercholesterolemia is an important risk factor for atherosclerotic vascular disease including stroke." | ( Harazny, J; Michelson, G; Ott, C; Schlaich, MP; Schmidt, BM; Schmieder, RE, 2008) |
| "Hypercholesterolemia is a well-established risk factor for the development of vascular events." | ( Iuchi, A; Miyoshi, H; Mizuguchi, Y; Nagase, N; Oishi, Y; Oki, T, 2008) |
| "Although hypercholesterolemia is known to impair endothelium-dependent vasodilation (EDV) long before the appearance of atherosclerotic plaques, it remains unclear whether the immune mechanisms that have been implicated in atherogenesis also contribute to the early oxidative stress and endothelial cell dysfunction elicited by hypercholesterolemia." | ( Granger, DN; Stokes, KY; Wolfort, RM, 2008) |
| "Hypercholesterolemia is associated with decreased vascular nitric oxide bioavailability and deletion of endothelial nitric oxide synthase (eNOS) markedly accelerates atherosclerosis development in apolipoprotein E knockout (apoE ko) mice." | ( Bauersachs, J; Ertl, G; Hu, K; Huang, PL; Kuhlencordt, PJ; Padmapriya, P; Rützel, S; Schäfer, A; Schödel, J, 2009) |
| "Hypercholesterolemia is one of the major risk factors for the development of cardiovascular disease." | ( Li, Y; Lu, N; Qin, H; Sun, CH; Zhang, YL, 2008) |
| "Hypercholesterolemia is one of the major causes of coronary heart disease (CHD)." | ( Abifadel, M; Boileau, C; Devillers, M; Erlich, D; Junien, C; Munnich, A; Rabès, JP; Varret, M, 2009) |
| "Hypercholesterolemia is the most important risk factor for cardiovascular diseases." | ( Alavi Majd, H; Ataie-Jafari, A; Larijani, B; Tahbaz, F, 2009) |
| "Hypercholesterolemia is a critical problem in patients with carotid atherosclerosis." | ( Calder, PC; Gallagher, PJ; Grimble, RF; Rerkasem, K; Shearman, CP, 2008) |
| "Hypercholesterolemia is a major risk factor for the development and progression of cardiovascular diseases including atherosclerosis." | ( Chan, SW; Chen, SL; Cheng, HL; Guo, DJ; Li, Q; Wu, JH, 2009) |
| "Hypercholesterolemia is a common problem among transplant recipients." | ( Almutairi, F; Alwayn, I; Molinari, M; Peltekian, KM; Peterson, TC; Walsh, MJ, 2009) |
| "Hypercholesterolemia is a common accompaniment of atherosclerosis and may be associated with cardiac hypertrophy." | ( Kang, BY; Mehta, JL; Palade, P; Sharma, SG; Wang, W, 2009) |
| "Hypercholesterolemia is prevalent in patients who experience myocardial ischemia-reperfusion injury (IR)." | ( Bianchi, C; Clements, RT; Feng, J; Glazer, HP; Liu, Y; Osipov, RM; Robich, MP; Sellke, FW; Sodha, NR, 2009) |
| "Hypercholesterolemia is one of the predisposing factors of cardiovascular diseases." | ( Fereshtehnejad, SM; Homayounfar, R; Kalani, A; Shidfar, F, 2009) |
| "Hypercholesterolemia is associated with impaired neovascularization in response to ischemia." | ( Dussault, S; Groleau, J; Haddad, P; Maingrette, F; Ménard, C; Michaud, SE; Perez, G; Rivard, A; Turgeon, J, 2009) |
| "Hypercholesterolemia is a major risk factor for cardiovascular disease." | ( Böhm, M; Laufs, U; Lütjohann, D; Weingärtner, O, 2010) |
| "Hypercholesterolemia is associated with decreased nitric oxide (NO) bioavailability and endothelial dysfunction, a phenomenon thought to have a major role in the altered cerebral blood flow evident in stroke." | ( Ahluwalia, A; Duchene, J; Hattori, N; Milsom, AB; Panayiotou, C; Urabe, T; Yamashiro, K, 2010) |
| "Hypercholesterolemia is a known risk factor for cardiovascular disease, and statin therapy has led to a significant reduction in morbidity and mortality from adverse cardiac events, stroke, and peripheral arterial disease." | ( Gahtan, V; Maier, KG; Sadowitz, B, 2010) |
| "Moreover, when hypercholesterolemia is associated with low concentrations of high-density lipoprotein (HDL)-cholesterol and high triglyceride levels, the association of statins with nicotinic acid, fibrates or omega-3 should be considered." | ( Ascaso, JF, 2010) |
| "Hypercholesterolemia is a predominant risk factor for atherosclerosis and associated coronary and cerebrovascular diseases." | ( Deng, R, 2009) |
| "First, hypercholesterolemia is associated with increased intestinal cholesterol absorption." | ( Ishibashi, T; Takeishi, Y, 2011) |
| "Hypercholesterolemia is a major risk factor for cardiovascular diseases that has been managed mostly with 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors (statins) that suppress de novo cholesterol synthesis in the liver." | ( Ikeda, S; Maemura, K, 2011) |
| "The development of hypercholesterolemia is a multifactorial process in which elevated plasma cholesterol levels play a central role." | ( Gui, SY; Jiang, ZK; Wang, Y; Zhou, Q; Zhu, HQ, 2011) |
| "Hypercholesterolemia is a major risk factor for cardiovascular diseases." | ( Böhm, M; Laufs, U; Lütjohann, D; Weingärtner, O, 2011) |
| "Hypercholesterolemia is one of the major risk factors for atherosclerosis." | ( Al-Mekhlafi, HM; Amran, AA; Das, S; Nordin, NA; Othman, F; Zakaria, Z, 2011) |
| "Hypercholesterolemia is one of the most representative disorders of the common diseases." | ( Araki, R; Hata, S; Ise, T; Kimura, H; Miyazaki, Y; Naruse, M; Ogo, A; Ohtani, S; Saito, M; Sawamura, M; Shimatsu, A; Shimbo, T; Tagami, T; Tanaka, M; Tanaka, T; Yonezawa, K, 2011) |
| "Hypercholesterolemia is one of the main factors in the development of atherosclerotic cardiovascular disease." | ( Markel, A, 2011) |
| "Homozygous familial hypercholesterolemia is an important risk factor for atherosclerosis and premature coronary artery disease in children and young adults." | ( Alves, C; Braid, Z, 2011) |
| "Hypercholesterolemia is also associated with increased oxidative stress." | ( Graham, LM; Miyazaki, K; Rosenbaum, MA, 2012) |
| "Whether hypercholesterolemia is a risk factor for contrast-induced acute kidney injury (CI-AKI) remains unclear." | ( Lin, S; Shang, W; Wei, L; Yang, D, 2012) |
| "Hypercholesterolemia is a major risk factor for atherosclerosis." | ( Antoniak, S; Curtiss, LK; Daugherty, A; Dutton, JA; Furie, B; Furie, BC; Hubbard, BK; Johns, DG; Kirchhofer, D; Luyendyk, JP; Mackman, N; Marshall, SM; McDaniel, AL; Moriarty, PM; Nagarajan, S; Owens, AP; Passam, FH; Rudel, L; Temel, RE; Tobias, PS; Wang, J; Williams, JC, 2012) |
| "Hypercholesterolemia is one of the cardiovascular risk factors sensitive to preventive and control interventions." | ( Jia, B; Kang, A; Wang, X; Wen, Z; Xie, L; Yao, W, 2012) |
| "Hypercholesterolemia is known to be a risk factor for Alzheimer's disease (AD), and diet-induced hypercholesterolemia has been shown to accelerate amyloid pathology in animals." | ( Idomoto, T; Kitajima, E; Klein, WL; Lambert, MP; Mori, H; Nomura, S; Tomiyama, T; Umeda, T, 2012) |
| "Hypercholesterolemia is a major risk factor for the development of cardiovascular disease and nonalcoholic fatty liver disease." | ( Chan, RY; Chan, SW; Kwok, CY; Pin, WK; Wan, CW; Wong, CN; Wong, MH; Yu, PH, 2013) |
| "Hypercholesterolemia is an important risk factor for cardiovascular disease." | ( Groen, AK; van der Wulp, MY; Verkade, HJ, 2013) |
| "Hypercholesterolemia is a major risk factor for atherosclerosis and related occlusive vascular diseases." | ( Akcay, DY; Kerry, Z; Kirkali, G; Sevin, G; Yasa, M, 2013) |
| "Hypercholesterolemia is a well established risk factor for cardiac cell apoptosis." | ( Chang, MH; Chen, TS; Cheng, YC; Fan, CC; Huang, CY; Lai, CH; Lin, CC; Lin, JA; Tsai, CC; Tsai, FJ, 2013) |
| "Hypercholesterolemia is a known risk factor for Alzheimer's disease (AD)." | ( Bae, SS; Choi, BT; Choi, KH; Jang, YJ; Kim, JH; Park, SH; Shin, HK, 2013) |
| "Hypercholesterolemia is a strong risk factor for myocardial infarction (MI)." | ( Acevedo, M; Corbalán, R; Giugliano, RP; Martínez, G; Navarrete, C; Rigotti, A; Rosales, J, 2013) |
| "Hypercholesterolemia is associated with an increased risk of heart disease." | ( Fakler, P; Ried, K; Toben, C, 2013) |
| "Hypercholesterolemia is a major risk factor for cardiovascular disease and requires continuous management." | ( Kang, HC; Kim, CM; Kim, YS; Lee, JA; Lee, SY; Oh, HJ; Park, KC; Sin, DH; Sunwoo, S; Yang, YJ; Yu, BY, 2013) |
| "Hypercholesterolemia is one of the major factors contributing to the risk of cardiovascular disease (CVD), which is the leading cause of death in developed countries." | ( Bhatnagar, D; Boue, SM; Huang, H; Wang, TT; Xie, Z; Yokoyama, W; Yu, LL, 2013) |
| "Hypercholesterolemia is a risk factor for the development of hypertrophic cardiomyopathy." | ( Barnes, S; Bradley, WE; Darley-Usmar, VM; Dell'Italia, LJ; Garber, DW; Hill, BG; Landar, A; Parks, DA; Perez, J; Prasain, J; Ulasova, E, 2013) |
| "Autosomal recessive hypercholesterolemia is a rare inherited disorder, characterized by extremely high total and low-density lipoprotein cholesterol levels, that has been previously linked to mutations in LDLRAP1." | ( Altshuler, D; Ardissino, D; Auer, PL; Barnes, TA; Charnas, L; de Faire, U; Defesche, JC; Duga, S; Erdmann, J; Farrall, M; Fouchier, SW; Gabriel, S; Gigante, B; Girelli, D; Goel, A; Hovingh, GK; Jackson, RD; Kastelein, JJ; Kathiresan, S; Kooperberg, C; Lange, LA; Martinelli, N; McPherson, R; Melander, O; Moscoso, AM; Nederveen, AJ; Nikpay, M; Orho-Melander, M; Peloso, GM; Rader, DJ; Reilly, MP; Samani, NJ; Schunkert, H; Sivapalaratnam, S; Sjouke, B; Stitziel, NO; Watkins, H, 2013) |
| "Hypercholesterolemia is a risk factor for estrogen receptor (ER)-positive breast cancers and is associated with a decreased response of tumors to endocrine therapies." | ( Carver, NJ; Geradts, J; Howe, MK; Jasper, JS; McDonnell, DP; Nelson, ER; Park, S; Pillai, RV; Sondhi, V; Suchindran, S; Sullivan, PM; Umetani, M; Wardell, SE, 2013) |
| "Hypercholesterolemia is one of the most important risk factors for erectile dysfunction, mostly due to the impairment of oxidative stress and endothelial function in the penis." | ( Costa-Fraga, FP; da Silva, RF; dos Santos, RA; Faye, Y; Fraga-Silva, RA; Lenglet, S; Mach, F; Montecucco, F; Savergnini, SQ; Steffens, S; Stergiopulos, N, 2013) |
| "Hypercholesterolemia is a prevalent risk factor for the development of erectile dysfunction (ED), mostly due to an increase in oxidative stress and impaired nitric oxide (NO) bioavailability within the penis." | ( Costa-Fraga, FP; da Silva, RF; Faye, Y; Fraga-Silva, RA; Santos, RA; Stergiopulos, N; Sturny, M, 2014) |
| "Hypercholesterolemia is certainly due to CI, therapy reduces cholesterol levels that not always fall below 200 mg/dl and this condition persists over time." | ( Campanella, N; Catozzo, V; Ferretti, M; Morosini, P; Sampaolo, G; Vichi, G, 2014) |
| "Familial hypercholesterolemia is an autosomal dominant inherited disease characterized by elevated plasma low-density lipoprotein cholesterol (LDL-C)." | ( Pan, XD; Sun, LY; Wang, LY; Wu, WF; Yang, SW, 2014) |
| "Hypercholesterolemia is a major cause of coronary heart disease." | ( Ghosh, M; Sengupta, A, 2014) |
| "Hypercholesterolemia is considered one of the most important risk factors and consequently a primary therapeutic target." | ( Lozzi, A, 2014) |
| "Hypercholesterolemia is a major contributor for disease burden in both the developed and developing world and an important risk factor for cardiovascular diseases (CVD)." | ( Castellanos-Jankiewicz, A; Del Bosque-Plata, L; Tejero, ME, 2014) |
| "Hypercholesterolemia is a condition characterised with high level of cholesterol in the blood." | ( Olaiya, CO; Omolekan, TO, 2013) |
| "Hypercholesterolemia is a well-established modifiable cardiovascular risk factor and its treatment is an essential aim in preventing cardiovascular disease." | ( Mannarino, MR; Ministrini, S; Pirro, M, 2014) |
| "Although hypercholesterolemia is a major risk factor for coronary artery disease (CAD), only limited data are available regarding its direct effect on myocardial function apart from CAD." | ( Han, W; Liu, L; Mu, Y; Wang, C, 2014) |
| "Hypercholesterolemia is a well-established risk factor for the development of kidney injury." | ( Balarini, CM; Carminati, RZ; Carneiro, SS; Freitas, FP; Gava, AL; Graceli, JB; Meyrelles, SS; Podratz, PL; Vasquez, EC, 2014) |
| "Hypercholesterolemia is a major risk factor for coronary artery disease and probiotics have been suggested as tools to manage elevated cholesterol levels." | ( Girard, P; Pansart, Y; Verleye, M, 2014) |
| "Since hypercholesterolemia is associated with an increase in the number and function of neutrophils, we hypothesized that this effect could be mediated through increased production of LTB4 in neutrophils." | ( Chang, J; Guo, LL; Lai, XF; Luo, ZG; Qin, CC; Qin, HD, 2014) |
| "Hypercholesterolemia is associated with increased oxidative stress and the development of neurotoxicity and Alzheimer's disease." | ( El-Sayyad, HI, 2015) |
| "Hypercholesterolemia is one of the factors contributing to cardiovascular problems." | ( Kiran, G; Nandini, CD; Salimath, PV; Srikanth, CB, 2015) |
| "Hypercholesterolemia is characterized by changes in lipid profile, nitric oxide pathway, and oxidative stress markers, but functions of high-density lipoprotein (HDL) were not well established in hypercholesterolemic subjects treated with atorvastatin." | ( Akalin Çiftçi, G; Akalin, A; Alataş, İÖ; Ertorun, İ; Musmul, A, 2015) |
| "Hypercholesterolemia is a cause of oxidative stress, endothelial dysfunction, and proinflammatory HDL levels." | ( Akalin Çiftçi, G; Akalin, A; Alataş, İÖ; Ertorun, İ; Musmul, A, 2015) |
| "Although hypercholesterolemia is a well-established risk factor for coronary heart disease, evidence suggests that increased triglyceride (TG) concentrations are also an independent risk factor." | ( Batista, R; Bochi, GV; da Luz, PL; Klafke, JZ; Moresco, RN; Porto, FG; Viecili, PR, 2015) |
| "Hypercholesterolemia is a common disorder in adult population, but total cholesterol concentrations beyond 1000 mg/dl occur rarely, and are found in patients with homozygous familial hypercholesterolemia and familial lecithin-cholesterol acyltransferase deficiency, in chronic graft-versus-host disease of the liver, after intravenous infusion of fat emulsion (intralipid), in newborn infants with immature liver function, and in obstructive biliary cholestasis." | ( Durlik, M; Jankowski, K; Pruszczyk, P; Tronina, O; Wierzbicka, A; Wyzgał, A, 2015) |
| "Hypercholesterolemia is a major risk factor for coronary artery disease (CAD)." | ( Abudoukelimu, M; Abudu, M; Adi, D; Chen, BD; Fu, ZY; Li, XM; Liu, F; Ma, YT; Maimaiti, A; Xie, X; Yang, YN; Zhu, Q, 2015) |
| "Familial hypercholesterolemia is a high risk constellation per se and LDL-cholesterol should be lowered early in life and significantly." | ( Vogt, A, 2015) |
| "Hypercholesterolemia is a metabolic disorder characterized by high levels of low-density lipoprotein and blood cholesterol, causing inflammatory lesion." | ( Cabral, FL; da Cruz, IB; da Silva, CB; Dos Santos, CB; Gonçalves, JF; Leal, DB; Lopes, ST; Machado, AK; Rezer, JF; Ruchel, JB; Schetinger, MR; Thorstenberg, ML, 2016) |
| "Hypercholesterolemia is a major risk factor for cardiovascular disease." | ( Alphonse, PA; Jones, PJ, 2016) |
| "Hypercholesterolemia is a common condition and is a risk factor for tendon rupture, specifically in the supraspinatus tendon." | ( Soslowsky, LJ; Tucker, JJ, 2016) |
| "Hypercholesterolemia is a major risk factor for cardiovascular diseases." | ( Elsässer, A; Lütjohann, D; Plösch, T; Weingärtner, O, 2017) |
| "Hyperglycemia and hypercholesterolemia are class effects of mammalian target of rapamycin inhibitors." | ( Basaran, M; Bodrogi, I; Bono, P; Bracarda, S; Brechenmacher, T; Escudier, B; Figlin, RA; Grunwald, V; Hutson, TE; Lin, C; Machiels, JP; Motzer, RJ; Oudard, S; Porta, C; Ravaud, A; Thompson, JA; Voi, M, 2016) |
| "Hypertension and hypercholesterolemia are highly prevalent in the general population and their coexistence in the same subjects additively increases the risk of cardiovascular disease." | ( Borghi, C; Cicero, AF; Urso, R, 2017) |
| "Hypertension and hypercholesterolemia are highly coprevalent and strongly related from a pathophysiological point of view." | ( Borghi, C; Cicero, AF; Urso, R, 2017) |
| "arguta for hypercholesterolemia are noted." | ( Bielecki, W; Gorinstein, S; Jesion, I; Latocha, P; Leontowicz, H; Leontowicz, M; Najman, K; Park, YS, 2016) |
| "Hypercholesterolemia is one of the important risk factors of atherosclerosis (AS)." | ( Liu, Y; Xu, Q; Xue, C; Yang, X; Zhang, X; Zhang, Y, 2017) |
| "Hypercholesterolemia is a known contributor to the pathogenesis of Alzheimer's disease while its role in the occurrence of Parkinson's disease (PD) is only conjecture and far from conclusive." | ( Borah, A; Choudhury, A; Giri, A; Kumar, S; Paul, R; Sandhir, R, 2017) |
| "Hypercholesterolemia is a marker for several adult chronic diseases." | ( Boarelli, PV; Cabrillana, ME; Fornés, MW; Funes, AK; Monclus, MA; Saez Lancellotti, TE; Simón, L; Vincenti, AE; Yapur, MA, 2017) |
| "Hypercholesterolemia is an atherosclerotic condition that is associated with impaired neovascularization in response to ischemia." | ( Desjarlais, M; Dhahri, W; Dussault, S; Mathieu, R; Rivard, A, 2017) |
| "Hypercholesterolemia is associated with reduced expression of miR-150, impaired Src signaling, and inefficient neovascularization in response to ischemia." | ( Desjarlais, M; Dhahri, W; Dussault, S; Mathieu, R; Rivard, A, 2017) |
| "Hypercholesterolemia is a known risk factor for cardiovascular diseases and affects a high proportion of the population." | ( Jia, SS; Li, H; Li, LX; Man, QQ; Song, PK; Zhang, J, 2017) |
| "Hypercholesterolemia is one of the major risk factors for the development of cardiovascular disease." | ( Johnston, TP; Korolenko, TA; Pirro, M; Sahebkar, A, 2017) |
| "Hypercholesterolemia is a strong determinant of mortality and morbidity associated with cardiovascular diseases and a major contributor to the global disease burden." | ( Dissanayake, V; Paththinige, CS; Sirisena, ND, 2017) |
| "Hypercholesterolemia is a serious diseases associated with type-2 diabetes, atherosclerosis, cardiovascular disorders and liver diseases." | ( Baiomy, AA; El-Sawy, HB; Saad, DY; Soliman, MM; Yassin, MH, 2017) |
| "Hypercholesterolemia is defined as LDL-C ≥ 100 mg/dL (2." | ( Baccara-Dinet, MT; Harada-Shiba, M; Ishigaki, Y; Kawabata, Y; Kiyosue, A; Kondo, A; Ozaki, A; Sata, M; Teramoto, T; Tobita, K, 2017) |
| "Hypercholesterolemia is an important risk factor linked to the alteration of blood hematology and clinical chemistry associated with the development and progression of atherosclerosis." | ( Ahmed, IA; Ibrahim, M; Mikail, MA, 2017) |
| "Hypercholesterolemia is one of the main risk factors for cardiovascular disease." | ( Goździkiewicz, N; Kasprzak, M; Krintus, M; Kubica, J; Obońska, E; Obońska, K; Racki, K; Sikora, J, 2017) |
| "In Ldlr-/- mice, hypercholesterolemia is related to a thrombotic CSVD phenotype, which is different from hypertension-related CSVD that associates with a hemorrhagic CSVD phenotype." | ( Carare, RO; Garz, C; Heinze, HJ; Jandke, S; Kleinschnitz, C; Kraft, P; Mencl, S; Schreiber, S; Schuhmann, MK; Urlaub, D; Zernecke, A, 2017) |
| "Hypercholesterolemia is a major risk factor upon developing cardiovascular diseases." | ( Kenawy, ME; Khamis, AA; Mohamed, TM; Salama, AF, 2017) |
| "But, when hypercholesterolemia is still moderate the consumption of food products with cholesterol-lowering capacities is more desirable than using drugs." | ( Gil-Ramírez, A; Morales, D; Soler-Rivas, C, 2018) |
| "Maternal hypercholesterolemia is a risk factor to renal injury in rat pups at adulthood, especially if they feed a cholesterol-enriched diet after weaning." | ( Fonseca, FL; Helou, CMB; Santinho, MAR; Simião, AL; Volpini, RA, 2017) |
| "Hypercholesterolemia is a risk factor for the development of cardiac hypertrophy." | ( Bian, ZP; Chen, XJ; Ding, YZ; Gu, CR; Li, XZ; Wu, HF; Xu, JD; Yang, D, 2017) |
| "Hypercholesterolemia is one of primary risk factors of cardiovascular disease, together with metabolic syndrome, hypertension and diabetes." | ( Sima, P; Vannucci, L; Vetvicka, V, 2018) |
| "Hypercholesterolemia is one of the most important risk factors for development of cardiovascular diseases." | ( Ahmed, YM; Baothman, OAS; Kaleemuddin, M; Khan, I; Khan, TJ; Kuerban, A; Mehanna, MG; Siddiqui, AM; Yasir, M; Zamzami, MA, 2018) |
| "Hypercholesterolemia is a pathological condition which has been reported in 39% of the worlds' adult population." | ( Ahangari, N; Ghayour Mobarhan, M; Pasdar, A; Sahebkar, A, 2018) |
| "Hypercholesterolemia is a major risk factor for cardiovascular disorders and requires specific intervention through an adequate lifestyle (diet and physical exercise) and, if necessary, an appropriate drug treatment." | ( Airoldi, G; Ceccarini, G; Fierabracci, P; Jaccheri, R; Magno, S; Minale, M; Pelosini, C; Salvetti, G; Santini, F; Saponati, G; Vitti, J, 2018) |
| "Hypercholesterolemia is a well-established risk factor for cardiac damage, which can lead to cardiovascular diseases." | ( Li, M; Liu, H; Liu, Y; Pei, Z; Xu, J; Yang, F; Zhu, L, 2018) |
| "Hypercholesterolemia is a major risk factor for the initiation and development of nonalcoholic fatty liver disease and atherosclerosis." | ( Chong, GH; Ghazali, HM; Hamzah, H; Tan, CX, 2018) |
| "Hypercholesterolemia is an important risk factor for coronary heart disease." | ( Chen, G; Ding, F; Dong, T; Geng, C; Ji, C; Jin, W; Peng, F; Yin, F; Yu, B, 2018) |
| "Hypercholesterolemia is a preventable risk factor for atherosclerosis and cardiovascular disease." | ( Li, R; Liu, Y; Lu, H; Shi, J; Yu, L; Yu, Y; Zhang, F, 2019) |
| "Hypercholesterolemia is associated with the development of a pro-inflammatory state and is a documented risk factor for progression to insulin resistance, nonalcoholic fatty liver and cardiovascular diseases." | ( Forney, LA; Gettys, TW; Kumar, A; Murthy, SN; Palfrey, HA; Pathak, R; Raju, NR; Stone, KP, 2019) |
| "Hypercholesterolemia is common in captive Psittaciformes." | ( Barboza, T; Beaufrère, H, 2019) |
| "Familial hypercholesterolemia is a relatively common 'genetic' disorder associated with an extremely high risk of developing coronary artery disease." | ( Kawashiri, MA; Nohara, A; Tada, H, 2019) |
| "Hypercholesterolemia is a major risk factor for cardiovascular disease (CVD)." | ( He, X; Liang, L; Liu, S; Peng, C; Xiao, C; Zhang, G; Zhao, S, 2019) |
| "Hypercholesterolemia is the leading cause of cardiovascular disease worldwide." | ( Jiang, B; Qu, T; Ren, D; Shen, M; Wang, Y; Yang, L, 2020) |
| "Hypercholesterolemia is the major risk factor in the development of coronary heart disease." | ( Cahyaningsih, P; Harahap, Y; Iskandar, I; Prasaja, B; Sandra, M; Wijayanti, TR, 2020) |
| "Hypercholesterolemia is a hazard for increasing susceptibility of the heart to myocardial infarction (MI) by inducing platelet hyperaggregability." | ( Atef, H; Atteia, HH; El-Sherbiny, M; Ibrahim, GA; Makary, S; Mohamed, AS; Mohammad, HMF; Zaitone, SA, 2020) |
| "Hypercholesterolemia is known to attenuate the cardioprotective effect of preconditioning; nevertheless, the exact underlying mechanisms are not clear." | ( Bodai, L; Csont, T; Diószegi, P; Gáspár, R; Pipicz, M; Sárközy, M; Szabó, MR; Zsindely, N, 2020) |
| "Hypercholesterolemia is a common dyslipidemia that leads to atherosclerosis." | ( Asadi, M; Heshmat, R; Kelishadi, R; Molavi, F; Motlagh, ME; Namazi, N; Qorbani, M; Sanjari, M; Shafiee, G, 2020) |
| "Hypercholesterolemia is a major risk factor for several cardiovascular and metabolic diseases as it triggers oxidative and pro-inflammatory cascades." | ( Al-Rejaie, SS; Alahmari, AA; Almalki, MS; Almutham, I; AlSaad, AM; AlSulaiman, M; Mohany, M, 2020) |
| "Monogenic familial hypercholesterolemia is characterized by impaired cellular uptake of apolipoprotein B containing lipoproteins." | ( Catanozi, S; Cazita, PM; Nakandakare, ER; Nunes, VS; Quintão, ECR, 2020) |
| "Hypercholesterolemia is a comorbidity of obesity and also linked to several cancers." | ( Asghari, A; Umetani, M, 2020) |
| "Hypercholesterolemia is a causal and modifiable risk factor for atherosclerotic cardiovascular disease." | ( Emmer, BT; Ginsburg, D; Graham, SE; Lascuna, PJ; Sherman, EJ; Willer, CJ, 2021) |
| "Hypercholesterolemia is an independent risk factor of cardiovascular disease, which is among the major causes of death worldwide." | ( Chen, W; Jiang, J; Narbad, A; Wu, C; Yu, L; Zhai, Q; Zhang, C; Zhang, H; Zhang, Q; Zhao, J, 2021) |
| "Hypercholesterolemia is characterized by the elevation of plasma total cholesterol level, especially low-density lipoprotein (LDL) cholesterol." | ( Chen, M; Hou, GF; Jin, YX; OuYang, YN; Tian, Z; Yang, PF; Zhou, LX, 2021) |
| "Hypercholesterolemia is a major risk factor for cardiovascular diseases." | ( Diaconu, CC; Furtunescu, F; Iorga, RA; Katsiki, N; Rizzo, M; Stoian, AP, 2021) |
| "Hypercholesterolemia is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD)." | ( Smith, SC; Stouffer, GA; Zhou, R, 2021) |
| "Hypercholesterolemia is a major risk factor for atherosclerosis and cardiovascular diseases." | ( Besnard, P; Gaillard, D; Garo, E; Grober, J; Masson, D; Pais de Barros, JP; Schoonjans, K; Souidi, M; Thomas, C, 2021) |
| "Hypercholesterolemia is caused by cholesterol homeostasis (CH) disruption, and it contributes to cardiovascular diseases pathogenesis and progression." | ( Antonic, T; Bogavac-Stanojevic, N; Gojkovic, T; Kotur-Stevuljevic, J; Spasojevic-Kalimanovska, V; Vekic, J; Vladimirov, S; Zeljkovic, A, 2021) |
| "Hypercholesterolemia is one of the principal causes of the development of cardiovascular diseases." | ( Fernández-Calderón, MC; Rincón, EO; Sánchez-Moro, MDH, 2022) |
| "Hypercholesterolemia is a major cause of cardiovascular disease and statins, the HMGCoA inhibitors, are the most prescribed drugs." | ( Galla, R; Molinari, C; Penna, C; Ruga, S; Uberti, F, 2022) |
| "Hypercholesterolemia is becoming a problem with increasing significance." | ( Haldar, S; Henry, CJ; Jiang, YR; Lim, KJ; Lim, RRX; Moskvin, OV; Nagarajan, N; Park, MA; Wong, LH, 2022) |
| "The treatment of hypercholesterolemia is mainly based on statins." | ( Leal, K; Paez, I; Prado, Y; Rojas, G; Saavedra, K; Saavedra, N; Salazar, LA; Ubilla, CG, 2022) |
| "Hypercholesterolemia is found in patients with chronic lung inflammation, during which airway epithelial cells play important roles in maintenance of inflammatory responses to pathogens." | ( Gu, Y; Li, L; Liu, X; Liu, Y; Song, Y; Wang, X; Zheng, N, 2022) |
| "Hypercholesterolemia is considered a novel risk factor for the development of OA." | ( Abolbashari, S; Eid, AH; Karimian, MS; Modaghegh, MHS; Saberianpour, S; Sahebkar, A; Sathyapalan, T, 2022) |
| "Hypercholesterolemia is defined as a high risk factor for causing female infertility by changing the cholesterol level in granulosa cells to impair the microenvironment of oocyte development and maturation." | ( Li, MQ; Li, YY; Liao, HQ; Wu, LJ; Zhou, J, 2022) |
| "Hypercholesterolemia is a significant risk factor for cardiovascular diseases such as coronary heart disease." | ( Chang, J; Liang, B; Liu, N; Liu, W; Meng, J; Shi, L; Wang, C; Wen, J; Xing, D; Xing, K; Yang, S; Zeng, J; Zhang, R, 2022) |
| "Hypercholesterolemia is recognized as cause of atherosclerosis, cerebro- and cardiovascular disease, and, closely related to this, is the widespread acceptance that it strongly contributes to platelet hyperreactivity via direct oxidized LDL (oxLDL)-platelet membrane interaction via scavenger receptors such as CD36 and signaling pathways including Src family kinases (SFK), mitogen-activated protein kinases (MAPK), and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase." | ( Barale, C; Melchionda, E; Morotti, A; Russo, I, 2022) |
| "The key to treating hypercholesterolemia is lowering plasma cholesterol levels." | ( Chang, J; Han, N; Hu, X; Li, H; Li, J; Liang, B; Liu, W; Lu, C; Meng, J; Shi, L; Wang, C; Wang, X; Xing, D; Yang, S; Zeng, J; Zhang, R, 2022) |
| "Hypercholesterolemia is a major driver of atherosclerosis, thus contributing to high morbidity and mortality worldwide." | ( Ballanti, M; De Angelis, L; Federici, M; Kappel, BA; Marx, N; Menghini, R; Puetz, A, 2023) |
| "Hypercholesterolemia is a major driver of atherosclerosis, thus contributing to high morbidity and mortality worldwide." | ( Ballanti, M; De Angelis, L; Federici, M; Kappel, BA; Marx, N; Menghini, R; Puetz, A, 2023) |
| "Hypercholesterolemia is a major driver of atherosclerosis, thus contributing to high morbidity and mortality worldwide." | ( Ballanti, M; De Angelis, L; Federici, M; Kappel, BA; Marx, N; Menghini, R; Puetz, A, 2023) |
| "Hypercholesterolemia is a common cause of cardiovascular diseases (CVDs)." | ( Dechtrirat, D; Jeenduang, N; Makarasen, A; Nawaka, N; Techasakul, S; Wanmasae, S, 2022) |
| "Hypercholesterolemia is a common cause of cardiovascular diseases (CVDs)." | ( Dechtrirat, D; Jeenduang, N; Makarasen, A; Nawaka, N; Techasakul, S; Wanmasae, S, 2022) |
| "Hypercholesterolemia is a common cause of cardiovascular diseases (CVDs)." | ( Dechtrirat, D; Jeenduang, N; Makarasen, A; Nawaka, N; Techasakul, S; Wanmasae, S, 2022) |
| "Since hypercholesterolemia is often present in individuals with sitosterolemia, it is important to search for genetic variants in ABCG5 and ABCG8 in patients with clinical criteria for familial hypercholesterolemia (FH), but no variants in FH implicated genes." | ( Chacra, APM; Miname, MH; Mizuta, MH; Rocha, VZ; Tada, MT, 2023) |
| "Hypercholesterolemia is associated with tendon pathology, but the reasons underpinning this relationship are not well understood." | ( Lee, J; Mousavizadeh, R; Scott, A; Screen, HRC; Waugh, CM, 2023) |
| "Hypercholesterolemia is a major causal risk factor for IHD." | ( Norata, GD; Pirillo, A, 2023) |
| "Hypercholesterolemia is a significant risk factor for cardiovascular disease and metabolic disorders." | ( Chantarangkul, C; Kasorn, A; Puttarat, N; Tangwattanachuleeporn, M; Taweechotipatr, M; Vitheejongjaroen, P, 2023) |
| Excerpt | Reference |
|---|
| "Current guidelines for detecting and treating hypercholesterolemia in adults render large numbers of elderly patients eligible for medical intervention." | ( Bilheimer, DW, 1991) |
| "The decision to treat hypercholesterolemia must take into account both the risk of death and myocardial infarction and the risk/benefit ratio of treatment." | ( Brunelli, C; Caponnetto, S; Corsiglia, L; Ghigliotti, G; Saccani, A; Spallarossa, P, 1991) |
| "Although diet therapy is the primary treatment for hypercholesterolemia, a trial to determine the effectiveness of the new American Heart Association Step One Diet (AHA diet) in lowering cholesterol has to our knowledge never been carried out." | ( Bae, CY; Keenan, JM; McCaffrey, DJ; Wenz, J, 1991) |
| "Dietary recommendations for the treatment of hypercholesterolemia (HC) emphasize stepwise reductions in fat intake, but there is no agreement on what lower limit is desirable or achievable." | ( Dowdy, A; Fish, B; Fitzpatrick, V; Follette, W; Gey, G; Hanson, M; McCann, BS; Parker, D; Retzlaff, B; Walden, CE, 1991) |
| "Would the money spent on treating hypercholesterolemia save more lives if spent elsewhere? How many dollars must be spent on a treatment to make one person live 1 year longer? This cost-effectiveness analysis uses the cost per year of life gained to compare a wide variety of health care interventions ranging from carcinogen research to screening tests to liver transplants." | ( Kelley, MD, 1990) |
| "Lovastatin is clinically used to treat patients with hypercholesterolemia and successfully lowers cholesterol levels." | ( Folkers, K; Langsjoen, P; Richardson, P; Tamagawa, H; Willis, R; Xia, LJ; Ye, CQ, 1990) |
| "There are indications that treatment of hypercholesterolemia by means of drugs reduce risk of atherosclerosis in patients with increased concentrations of atherogenic lipoproteins." | ( Blomhoff, JP; Ose, L; Torsvik, H, 1989) |
| "Family physician recognition and treatment of severe hypercholesterolemia was determined in a residency program by chart audit." | ( Madlon-Kay, DJ, 1987) |
| "The surgical treatment of hypercholesterolemia and the treatment of homozygous and other forms of hypercholesterolemia are also detailed." | ( Kane, JP; Malloy, MJ, 1982) |
| "In conclusion, long-term treatment of hypercholesterolemia with fluvastatin at dosages of 20-40 mg daily can be considered both safe and effective." | ( Goto, Y; Itakura, H; Kurokawa, K; Nakamura, H; Nakaya, N; Saito, Y; Takaku, F; Teramoto, T; Yamada, N; Yoshida, S, 1995) |
| "Diet therapy is effective in the treatment of hypercholesterolemia in children and adolescents." | ( Arnaiz, P; Asensio, J; Baeza, J; Gonzalez-Requejo, A; Ruiz-Jarabo, C; Sanchez-Bayle, M; Vila, S, 1994) |
| "Pravastatin treatment of hypercholesterolemia is highly effective and well tolerated alone and in combination with bile acid-binding resin and shows no tendency to increase muscle enzyme levels." | ( , 1993) |
| "Simvastatin, a drug for the treatment of hypercholesterolemia, is a competitive inhibitor of 3-Hydroxy-Methyl-Glutaryl-CoA reductase, the rate limiting enzyme in cholesterol biosynthesis." | ( Faggiano, P; Gardini, A; Ghizzoni, G; Oneglia, C; Rusconi, C; Sabatini, T, 1993) |
| "This larger incidence of treatment-requiring hypercholesterolemia in Nuremberg was distributed throughout all age groups up to the age of 60." | ( Rassoul, F; Richter, V; Richter, WO; Rotzsch, W; Schwandt, P; Sönnichsen, AC, 1993) |
| "69 subjects of both sexes under-going treatment for hypercholesterolemia (mean age 48 +/- 11 years) entered the study; 43 had been treated with simvastatin and 11 with pravastatin for 6 months; 15 only on dietary regimen served as controls." | ( Berardesca, E; Brazzelli, V; Distante, F; Perani, G, 1996) |
| "Current recommendations for the treatment of hypercholesterolemia include drug therapy for persons at sufficiently elevated risk for coronary heart disease." | ( Avins, AL; Browner, WS, 1996) |
| "Lovastatin is a popular drug for the treatment of hypercholesterolemia." | ( Chen, WJ; Chiang, CW; Chu, PH; Lee, YS, 1997) |
| "Probucol, a drug commonly employed for treatment of hypercholesterolemia, has antioxidant properties and inhibits oxidation of low density lipoproteins in vitro." | ( Fukai, T; Harrison, DG; Inoue, N; Nishida, K; Ohara, Y, 1998) |
| "Garlic therapy for treatment of hypercholesterolemia cannot be recommended on the basis of this study." | ( Berthold, HK; Sudhop, T; von Bergmann, K, 1998) |
| "To determine whether effective treatment of hypercholesterolemia may improve vasodilatory capacity of resistance vessels, the authors examined the impact of 12 and 24 weeks of lipid-lowering therapy with the hepatic hydroxymethylglutaryl coenzyme A (HMG-CoA)-reductase inhibitor fluvastatin (40 to 80 mg/day) on the increment in forearm blood flow during reactive hyperemia in 24 hypercholesterolemic patients (mean age: 56 +/- 11 years; 15 men/9 women)." | ( Schmieder, RE; Schobel, HP, 1998) |
| "In the long-term treatment of hypercholesterolemia, Niaspan produced favorable changes in LDL and HDL cholesterol, triglycerides, and lipoprotein(a)." | ( Goldberg, AC; Guyton, JR; Kreisberg, RA; O'Connor, CM; Sprecher, DL; Superko, HR, 1998) |
| "Children have been tested and treated for hypercholesterolemia for more than 30 years." | ( Black, DM, 2001) |
| "Naringin treatment inhibited hypercholesterolemia-induced intercellular adhesion molecule-1 (ICAM-1) expression on endothelial cells." | ( Bok, SH; Choe, SC; Jeong, TS; Kim, HS; Park, YB, 2001) |
| "There is clear evidence that treating hypercholesterolemia reduces cardiovascular risk in women, as well as in men." | ( Davidson, MH; Ingram, KA; Karp, SK; Maki, KC, 2002) |
| "Appropriate treatment of hypercholesterolemia occurred in 96% of patients referred to a clinical pharmacy specialist, compared with 68% of those followed by primary care providers alone (p<0." | ( Beckey, NP; Geber, J; Korman, L; Parra, D, 2002) |
| "Statins are widely used to treat hypercholesterolemia and atherosclerotic disease." | ( Badimon, JJ; Corti, R; Fayad, ZA; Fuster, V; Helft, G; Mercuri, M; Mizsei, G; Smith, D; Weinberger, J; Wentzel, J; Worthley, SG, 2002) |
| "These findings support treatment of hypercholesterolemia in this population." | ( Coresh, J; Eustace, JA; Fink, NE; Jaar, B; Klag, MJ; Liu, Y; Longenecker, JC; Powe, NR; Tracy, RP, 2004) |
| "The percent of people with treated hypercholesterolemia was higher in the younger patients." | ( Chizyński, K, 2003) |
| "Fluvastatin has been used safely to treat hypercholesterolemia in renal transplant patients but there are few data relating to its use after heart transplantation." | ( Banner, NR; Barbir, M; Mitchell, AG; O'Rourke, B; Yacoub, MH, 2004) |
| "Prevention and treatment of hypercholesterolemia should be an important component of a national strategy to reduce the substantial and increasing burden of cardiovascular disease in China." | ( Chen, J; Gu, D; He, J; Liu, D; Mo, J; Muntner, P; Reynolds, K; Whelton, PK; Wu, X; Zhao, J, 2004) |
| "In conclusion, atorvastatin not only treated hypercholesterolemia but also favorably affected the uremic lipid profile in patients on hemodialysis." | ( Billiouw, JM; Carpentier, YA; Dratwa, M; Ducobu, J; Dupont, P; Lameire, NH; Lins, RL; Maes, B; Matthys, KE; Peeters, PC; Stolear, JC; Tielemans, C; Verpooten, GA, 2004) |
| "Statins represent a very effective treatment of hypercholesterolemia, and the co-administration of drugs with complementary mechanisms of action, may represent an additional pharmacological tool in clinical practice to achieve the suggested targets for LDL lowering." | ( Catapano, AL; Catapano, L; Fellin, R, 2004) |
| "Eighteen patients with so far untreated hypercholesterolemia were involved in our study." | ( Jehlicka, P; Mayer, O, 2005) |
| "However, the treatment of hypercholesterolemia should be improved." | ( Alperin, M; Goldfracht, M; Hermoni, D, 2006) |
| "Whether it is preferable to treat hypercholesterolemia with statins or to switch patients from CsA to tacrolimus (TRL) has not been investigated." | ( Abramowicz, D; Berkenboom, G; Broeders, N; Carpentier, Y; Ghisdal, L; Unger, P; Wissing, KM, 2006) |
| "Atorvastatin treatment reverses hypercholesterolemia-induced endothelial dysfunction without appreciable improvements in collateral-dependent myocardial perfusion in response to vascular endothelial growth factor treatment." | ( Boodhwani, M; Feng, J; Li, J; Mieno, S; Sellke, FW; Sodha, N; Voisine, P, 2006) |
| "Statins are increasingly used in the treatment of hypercholesterolemia." | ( Davidson, M; Gandhi, SK; Kamat, SA, 2007) |
| "Four patients received treatment for hypercholesterolemia." | ( Amaral, SG; Greenbaum, LA; Hymes, LC; Warshaw, BL, 2008) |
| "Statin treatment reduces hypercholesterolemia and may be anti-inflammatory." | ( Allina, J; Bach, N; Bodenheimer, H; Bodian, C; Odin, JA; Stanca, CM, 2008) |
| "Fluvastatin treatment for hypercholesterolemia in patients with MetS is associated with a decrease in serum ADMA levels at 6 weeks." | ( Oguz, A; Uzunlulu, M, 2008) |
| "The current standard of care for treating hypercholesterolemia is the use of HMG-CoA reductase inhibitors, also known as statins, which block the rate-limiting step of cholesterol biosynthesis." | ( Pfefferkorn, JA, 2009) |
| "Drugs to treat hypercholesterolemia should thus have sufficient longterm lipid-lowering and direct antiatherosclerotic effects." | ( Ohbayashi, H, 2010) |
| "Standard treatments for hypercholesterolemia include the HMG CoA reductase inhibitors, or "statins." | ( Abrams, DI; Couey, P; Kamanu-Elias, N; Kelly, ME; Shade, SB; Stamets, P, 2011) |
| "The primary target in the treatment of hypercholesterolemia is often to lower low-density lipoprotein (LDL) cholesterol, rather than improve clinical outcomes." | ( Doggrell, SA, 2012) |
| "Niacin has been used for years to treat hypercholesterolemia, but may not be as beneficial as thought for patients at high risk of cardiovascular disease." | ( Jones, KW, 2013) |
| "Statins are used to treat hypercholesterolemia in patients with type 2 diabetes mellitus, but many of these patients fail to achieve the target LDL-C level." | ( Arao, T; Hajime, M; Inokuchi, N; Kurozumi, A; Matsuoka, H; Mori, H; Narisawa, M; Okada, Y; Tanaka, K; Tanaka, Y; Torimoto, K; Yamamoto, S, 2013) |
| "A number of drugs are used to treat hypercholesterolemia like statin, fibrate, bile acid sequestrants, niacin, ezetimibe, omega-3 fatty acids and natural extracts." | ( Khokhar, M; Tiwari, V, 2014) |
| "Statins are the preferred treatment for hypercholesterolemia and several studies have demonstrated their long-term safety and efficacy in reducing cardiovascular morbidity and mortality." | ( Alonso, R; Cuevas, A; Farías, MM, 2014) |
| "Cholesterol analogs can be used to treat hypercholesterolemia." | ( Chen, ZY; Huang, W; Lei, L; Li, YM; Liu, Y; Ma, KY; Man, SW; Wang, L; Wang, X; Zhang, C; Zheng, F, 2015) |
| "A total of 68 patients with untreated isolated hypercholesterolemia were randomly allocated to either drinking H2-rich water (n = 34) or placebo water (n = 34) for 10 weeks." | ( Ding, G; Guo, S; Jiao, P; Lin, Q; Liu, M; Qin, S; Song, G; Sun, Y; Wu, Y; Xiao, Q; Ye, F; Yu, Y; Zhao, H, 2015) |
| "Statin treatment of hypercholesterolemia can lead to chronic myotoxicity which is, in most cases, alleviated by drug withdrawal." | ( Barragan, I; Battini, JL; Cousin, C; Egesipe, AL; Giraud-Triboult, K; Ingelman-Sundberg, M; Laustriat, D; Lotteau, V; Meyniel-Schicklin, L; Peric, D; Peschanski, M; Petit, V; Pinset, C; Sitbon, M; Touhami, J, 2015) |
| "Many drugs for the treatment of hypercholesterolemia are targeting the enzymes involved in human cholesterol biosynthesis pathway." | ( Chang, DK; Chen, YH; Huang, KJ; Lin, HK; Shiuan, D; Tai, DF, 2016) |
| "To assess changes in the treatment of hypercholesterolemia in Polish ambulatory care over the last 6 years." | ( Filipiak, KJ; Kapłon-Cieślicka, A; Kołtowski, Ł; Michalak, M, 2017) |
| "The most favorable change in the treatment of hypercholesterolemia is an increase in the proportion of patients treated with strong statins." | ( Filipiak, KJ; Kapłon-Cieślicka, A; Kołtowski, Ł; Michalak, M, 2017) |
| "The first line treatment for hypercholesterolemia is statin therapy." | ( Goździkiewicz, N; Kasprzak, M; Krintus, M; Kubica, J; Obońska, E; Obońska, K; Racki, K; Sikora, J, 2017) |
| "A promising approach to treat hypercholesterolemia is inactivating the secreted protein PCSK9, an antagonist of the LDL receptor." | ( Bartsevich, VV; Bell, P; Breton, C; Buza, EL; Calcedo, R; Che, Y; Clark, P; He, Z; Jantz, D; Lape, J; Li, M; Saveliev, A; Smith, J; Wang, L; White, J; Wilson, JM; Ying, L; Zhang, J, 2018) |
| "Statin drugs that were used for the treatment of hypercholesterolemia patients can interfere in the regulation of the immune response and cytokine secretion." | ( Ahangari, G; Arshad, M; Babaheidarian, P; Emruzi, Z; Stockinger, H, 2019) |
| "PCSK9 have been approved for the treatment of hypercholesterolemia and for the secondary prevention of cardiovascular events." | ( Bacalbasa, N; Bratu, OG; Crismaru, I; Diaconu, CC; Gaman, MA; Pantea Stoian, A; Stanescu, AMA, 2020) |
| "Bempedoic acid is an emerging treatment for hypercholesterolemia that has recently been approved for marketing in the United States and Europe." | ( Amodeo, V; Aspromonte, N; Caldarola, P; Cipriani, M; Colivicchi, F; Di Fusco, SA; Di Lenarda, A; Domenicucci, S; Francese, GM; Gabrielli, D; Gulizia, MM; Imazio, M; Murrone, A; Roncon, L; Scicchitano, P; Scotto di Uccio, F; Urbinati, S; Valente, S, 2021) |
| "Statins are prescribed to treat hypercholesterolemia and to reduce the risk of cardiovascular disease." | ( Angleys, M; Bundgaard, JR; Dela, F; Desler, C; Dohlmann, TL; Durhuus, JA; Hansson, S; Helge, JW; Hickson, ID; Kuhlman, AB; Larsen, S; Morville, T; Muniesa-Vargas, A; Rasmussen, LJ, 2020) |
| "It has a potential use for treating hypercholesterolemia in individuals who cannot take statins, and possibly as adjunctive to other agents, such as ezetimibe or bempedoic acid." | ( Bai, R; Di Bisceglie, AM; Lavin, P; Liu, L; Watts, GF; Yu, M, 2020) |
| "The use of nutritional supplements to treat hypercholesterolemia is gradually increasing, however further studies on their efficacy and safety are required." | ( Arnás, C; Corbella, E; de Dios, S; Florido, M; Licerán, M; Martin, D; Martinez-Martin, F; Petitbò, D; Pintó, X; Sánchez, A; Sánchez-Hernández, RM; Sarasa, I; Trias, F, 2022) |
| "The key to treating hypercholesterolemia is lowering plasma cholesterol levels." | ( Chang, J; Han, N; Hu, X; Li, H; Li, J; Liang, B; Liu, W; Lu, C; Meng, J; Shi, L; Wang, C; Wang, X; Xing, D; Yang, S; Zeng, J; Zhang, R, 2022) |